Medical News

RSS

MannKind receives FDA Complete Response letter for AFREZZA NDA

MannKind Corporation today announced that it has received a Complete Response letter from the U.S. Food & Drug Administration (FDA) regarding the New Drug Application (NDA) for AFREZZA™ (insulin human [rDNA origin]) Inhalation Powder for the treatment of adult patients with type 1 and type 2 diabetes mellitus for the control of hyperglycemia.

15 Mar 2010

Stimulus funds spur Indiana doctors, hospitals to switch to electronic records more quickly

The offer of federal stimulus funds is spurring Indiana health care providers to convert to electronic medical records, The (Fort Wayne, Ind.) Journal Gazette reports.

15 Mar 2010

CytRx plans five Phase 2 clinical trials with oncology drug candidates

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the twelve months ended December 31, 2009, and affirmed its 2010 milestones of commencing up to five Phase 2 clinical trials with its oncology drug candidates.

15 Mar 2010

COBRA health insurance program changes confuse consumers

Kaiser Health News staff writer Jenny Gold writes about the confusion currently surrounding consumers. "Every day, dozens of confused, laid-off workers call the COBRA Help Center in Long Island, N.Y., a small private company which administers COBRA group health insurance plans.

15 Mar 2010

Cardium Therapeutics closes $11.3M registered direct offering

Cardium Therapeutics, Inc. today reported it has closed its registered direct offering announced on March 9, 2010. The offering resulted in total gross proceeds to Cardium of $11.3 million, which included the full initial offering amount of $10.0 million, plus an additional overallotment amount purchased by institutional investors.

15 Mar 2010

Ranbaxy resolves generic Actos patent litigation

Ranbaxy Laboratories Limited, along with its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc. (collectively, "Ranbaxy"), announced today that they have reached an agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Ranbaxy's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15 mg, 30 mg and 45 mg tablets.

15 Mar 2010

Program to obtain transplant organs from ER patients creates controversy

The Washington Post: "In the hope of expanding a controversial form of organ donation into emergency rooms around the United States, a federally funded project has begun trying to obtain kidneys, livers and possibly other body parts from car-accident victims, heart-attack fatalities and other urgent-care patients.

15 Mar 2010

MicuRx Pharmaceuticals files IND for MRX-I antibiotic drug candidate with Chinese SFDA

MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that it has filed an Investigational New Drug (IND) application with the State Food and Drug Administration (SFDA) in China for MRX-I, its first development-stage antibiotic drug candidate. MRX-I, an orally-administered oxazolidinone, targets multi-drug resistant Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

15 Mar 2010

Metastatic melanoma: Involvement of immune system in response to PV-10 therapy

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that Dr. Sanjiv Agarwala, in his presentation at the Seventh International Symposium on Melanoma and Other Cutaneous Malignancies on March 12, 2010, commented on the involvement of the immune system in response to PV-10 therapy and its role in the “bystander effect” in treating metastatic melanoma. Dr. Agarwala’s presentation, entitled “Chemoablation in Melanoma: An Update,” was given in the session entitled “Unique Approaches to Melanoma Therapy.”

15 Mar 2010

LLS, FORMA Therapeutics collaborate to develop small molecule compounds against Bcl-6

The Leukemia & Lymphoma Society and FORMA Therapeutics, Inc., today announced they have begun a partnership to discover and develop small molecule compounds against a key lymphoma target, Bcl-6.

15 Mar 2010

Novo Growth Equity invests in Orexo

Orexo AB and Novo A/S today announced combined transactions encompassing a directed new issue by Orexo of a SEK 111 million convertible bond to Denmark-based Novo A/S and the acquisition of significant blocks of existing shares by Novo A/S from two existing venture capital shareholders, subject to approval at an Extraordinary General Meeting. The conversion price of the convertible bonds is set at 25 per cent premium to the closing share price on 12 March, 2010.

15 Mar 2010

Z-Medica announces the launch of QuikClot Grant for U.S. military veterans attending Marietta College

Z-Medica Corporation, a medical device company developing innovative hemostatic agents, today announced the launch of its QuikClot Grant for U.S. military veterans attending Marietta College. The $25,000 grant will support Marietta College’s Yellow Ribbon Program, which allows qualified veterans to attend the college as undergraduate students and receive full tuition scholarships.

From Medica Corporation 15 Mar 2010

Caliper Life Sciences enters into settlement agreement with Shimadzu and its subsidiary Shimadzu Scientific Instruments

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today announces that it has entered into a settlement agreement with Shimadzu Corporation and its wholly owned subsidiary Shimadzu Scientific Instruments, Inc., resolving a lawsuit filed by Caliper in the United States District Court for the Eastern District of Texas that claimed that Shimadzu's MultiNA microchip-based electrophoresis system infringed several U.S. patents relating to Caliper's microfluidic LabChip® technology.

15 Mar 2010

Cephalon Australia granted exclusive license to develop Innate Immune's antibodies for treatment of asthma, SLE

Innate Immune, Inc., a privately held biotechnology company, today announced that it has granted to Cephalon Australia Pty Ltd an exclusive license to patents for the development of its antibodies for the treatment of asthma and systemic lupus erythematosis (SLE).

15 Mar 2010

Enzo Biochem to market MultiGEN’s multiplex DNA sequencing based diagnostic tests in state of New York

Enzo Biochem, Inc. today announced that it has entered into an agreement with MultiGEN Diagnostics Inc., of San Diego, California, for exclusive rights to market MultiGEN’s unique diagnostic tests based on multiplex DNA sequencing, in the state of New York. In addition, Enzo has been granted marketing rights for other non-exclusive territories in United States.

15 Mar 2010

ZYTO's 2009 revenues up 65%

ZYTO Corp announced an increase of 65 percent in top line revenue for year-end 2009, compared to year-end 2008. Total revenue for 2009 was $3,206,148 (unaudited) up from $1,937,853 (audited) in 2008.

15 Mar 2010

Hemispherx Biopharma reports net loss of $13,438,000 for fiscal year 2009

Hemispherx Biopharma, Inc., announced its financial results for the fiscal year ended December 31, 2009. The net loss for the year (including non-cash charges) was approximately $13,438,000 or $0.12 per share as compared to a net loss of $12,219,000 or $0.16 per share in 2008.

15 Mar 2010

St. Jude Medical announces updates to PressureWire platform at ACC and SIR annual meetings

St. Jude Medical, Inc., a global medical device company, announced several updates to its PressureWire™ platform, including a new marketing agreement with Siemens Medical Solutions USA, for the wireless PressureWire™ Aeris and the availability of the next-generation of PressureWire™ Certus technology, at the American College of Cardiology and the Society of Interventional Radiology annual meetings.

15 Mar 2010

MBGH conduct national survey to improve employer-based health improvement and management programs

To better understand and improve the effectiveness of employer-based health improvement and management programs, the Midwest Business Group on Health, conducted a national survey of physician views on employers' health management programs.

15 Mar 2010

YM BioSciences: Two posters on nimotuzumab accepted for presentation at AACR

YM BioSciences Inc., today announced that two posters have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting to be held from April 17-21 in Washington, DC. The first poster describes the results of the previously reported collaboration with researchers at the University of Toronto for the development of highly potent antibody-radionuclide conjugates for use in the treatment of cancer. The poster will describe activity of 111In-NLS-nimotuzumab against breast cancer cells with high and low EGFR expression.

15 Mar 2010

Medical News

MannKind receives FDA Complete Response letter for AFREZZA NDA

Stimulus funds spur Indiana doctors, hospitals to switch to electronic records more quickly

CytRx plans five Phase 2 clinical trials with oncology drug candidates

COBRA health insurance program changes confuse consumers

Cardium Therapeutics closes $11.3M registered direct offering

Ranbaxy resolves generic Actos patent litigation

Program to obtain transplant organs from ER patients creates controversy

MicuRx Pharmaceuticals files IND for MRX-I antibiotic drug candidate with Chinese SFDA

Metastatic melanoma: Involvement of immune system in response to PV-10 therapy

LLS, FORMA Therapeutics collaborate to develop small molecule compounds against Bcl-6

Novo Growth Equity invests in Orexo

Z-Medica announces the launch of QuikClot Grant for U.S. military veterans attending Marietta College

Caliper Life Sciences enters into settlement agreement with Shimadzu and its subsidiary Shimadzu Scientific Instruments

Cephalon Australia granted exclusive license to develop Innate Immune's antibodies for treatment of asthma, SLE

Enzo Biochem to market MultiGEN’s multiplex DNA sequencing based diagnostic tests in state of New York

ZYTO's 2009 revenues up 65%

Hemispherx Biopharma reports net loss of $13,438,000 for fiscal year 2009

St. Jude Medical announces updates to PressureWire platform at ACC and SIR annual meetings

MBGH conduct national survey to improve employer-based health improvement and management programs

YM BioSciences: Two posters on nimotuzumab accepted for presentation at AACR

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News